India’s Global Leap: ₹10,000 Crore “Biopharma SHAKTI” to Transform Drug Innovation

In a landmark move for the healthcare sector, the Union Budget 2026-27 has unveiled a strategic blueprint to establish India as a premier global biomanufacturing hub. Finance Minister Smt. Nirmala Sitharaman introduced the “Biopharma SHAKTI” initiative—an ambitious ₹10,000 crore program designed to transition the nation from being the world’s pharmacy to its primary innovation laboratory.

Core Pillars of the 2026 Biopharma Strategy

Financial Powerhouse: The ₹10,000 crore outlay over five years specifically targets the production of high-value biologics and biosimilars, drastically reducing reliance on expensive foreign imports.
Clinical Research Infrastructure: To accelerate drug discovery, the government will establish 1,000+ accredited clinical trial sites. This move is set to enhance the global credibility of Indian research and provide patients with faster access to breakthrough therapies.
Regulatory Modernization: The Central Drugs Standard Control Organisation (CDSCO) will receive a specialized scientific review cadre to ensure that Indian regulatory approvals match stringent international benchmarks.
Academic Excellence: Education is receiving a massive upgrade with three new National Institutes of Pharmaceutical Education and Research (NIPERs) and the modernization of seven existing institutes to bridge the gap between academia and industry needs.

Why It Matters

This budget marks a shift toward “Healthcare Security.” By fostering a self-reliant ecosystem, India aims to lower the cost of next-generation treatments while creating thousands of high-skilled jobs for researchers and medical professionals.